CDMRP Breast Cancer Breakthrough Award Level 3

Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome.

Level 3 Awards support advanced translational studies that have potential for near-term clinical investigation. Small-scale clinical trials may apply.
 

It is expected that 2 awards will be granted. 

Funding : $5,600,000 total ($7M with a partner)

Duration: 4 years

Research Authority due date: 7.6.26

Pre proposal (required) due date: 12.6.26
Full proposal due date: 30.9.26